BАbykids Spray In Common Cold

Common Cold Clinical Trial

— BASICC  

Official title:

Efficacy and Safety of Healsea® Babykids in the Treatment of Acute Infectious Rhinitis Symptoms in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05819203
• Other study ID #: LPH-2202
• Status: Completed
• Phase: N/A
• Start date: February 13, 2023
• Est. completion date: May 16, 2023

Study information

• Verified date: April 2023
• Source: Lallemand Pharma AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this post market clinical investigation is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo in children above 2 years.

Description:

Healsea® Babykids is an isotonic saline solution based nasal spray supplemented with a natural Symbiofilm® extract (0.04%) isolated from marine bacteria. Symbiofilm® has in vitro antibiofilm activity and protects in vitro human nasal epithelial cells viability after Rhinovirus, Adenovirus, coronavirus OC43 and flu infection. Healsea® Babykids is a nasal spray indicated in children above 2 years to clean and moisten the nose during colds and rhinitis. The common cold is an acute viral infection of the upper respiratory tract, involving, to variable degrees, sneezing, nasal congestion and discharge (rhinorrhea), sore throat, cough, low-grade fever, headache, and malaise. Acute viral rhinitis is generally self-limiting. In children where the illness is not self-limiting and extends beyond 7-10 days, many agree that a bacterial infection is likely. Bacterial over infections and progression to a chronic state are favoured by the formation of biofilms, which facilitate bacterial growth and persistence as well as reducing antibiotic efficacy. The aim of this study is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo. The study comprises 2 parts: - Part 1 (Day 1-Day 11): treatment of the acute phase • with Healsea® Babykids, 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes of Healsea® Babykids) up to 10 days (20 intakes of the investigational device). or • with isotonic nasal spray (Placebo), 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes of Placebo) up to 10 days (20 intakes of the investigational device). - Part 2 (up to Day 15/Day 18): follow-up phase. The study comprises two visits: - Visit 1 (V1) at Day 1 - End of study visit (Visit 2, V2) between Day 15 and Day 18

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: May 16, 2023
• Est. primary completion date: May 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Months to 6 Years

Eligibility

Inclusion Criteria:

• 1. Male/Female subjects >2 and =6-year-old
• 2. Acute infectious rhinitis/rhinosinusitis for =48h before trial entry
• 3. Patient presenting with fever = 37.5 °C at screening
• 4. Subjects with nasal congestion (blocked / stuffy nose) rated at least as moderate on the Acute Rhinitis Symptoms Severity Questionnaire, based on evaluation by the investigator
• 5. Subjects showing at least moderate grade for at least one of the following additional signs of acute rhinitis: runny nose, nasal crust (dry mucus), sneezing and cough
• 6. Written consent obtained from parent/legal guardians

Exclusion Criteria:

• 1. Known hypersensitivity/allergy to any component of the test device
• 2. Medical history that is considered by the investigator as a reason for non-inclusion,
• 3. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps
• 4. History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores
• 5. Antibiotic intake within 2 weeks before screening
• 6. Systemic corticosteroids within 4 weeks before screening
• 7. Chronic decongestant use
• 8. Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence ARSSQ score at screening (NSAID, nasal decongestants, cough medicines)

Related Conditions & MeSH terms

• Common Cold
• Rhinitis

Intervention

Device:
• Healsea Babykids
7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .
• Placebo
7-day-treatment period (14 intakes ) up to 10 days (20 intakes) .

Locations

Country	Name	City	State
Bulgaria	Medical center	Plovdiv
Bulgaria	Medical center	Sofia
Bulgaria	Medical center	Vratsa

Sponsors (1)

Lead Sponsor	Collaborator
Lallemand Pharma AG

Country where clinical trial is conducted

Bulgaria, 

References & Publications (4)

Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diama — View Citation

Heikkinen T, Jarvinen A. The common cold. Lancet. 2003 Jan 4;361(9351):51-9. doi: 10.1016/S0140-6736(03)12162-9. — View Citation

Passioti M, Maggina P, Megremis S, Papadopoulos NG. The common cold: potential for future prevention or cure. Curr Allergy Asthma Rep. 2014 Feb;14(2):413. doi: 10.1007/s11882-013-0413-5. — View Citation

Principi N, Esposito S. Nasal Irrigation: An Imprecisely Defined Medical Procedure. Int J Environ Res Public Health. 2017 May 11;14(5):516. doi: 10.3390/ijerph14050516. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the curve (AUC) of the global score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) during first 10 days of symptoms	ARSSQ is a non-validated customized questionnaire . It includes 10 items assessing symptoms (questions 2 to 7), functional impairments (8 to 10), and global severity (question 1). Each item is scored from 0 (not present/no impact/ not sick) to 3 (severe, severe impact and very sick) for symptoms, functional impairment and global severity respectively. The questionnaire is to be completed in a diary once daily in the evening.	From Day 1 to Day 10
Secondary	Duration of each cold symptom (questions 2 to 7 of the ARSSQ) in both groups	For each separate symptom, the duration is defined as the number of days between Day 1 and the first day the parent/legal guardian reports the patient not having this symptom ("Not present") for 2 consecutive days.; Duration may be censored at Visit 2.	Through study completion, up to Day 18
Secondary	Duration of quality-of-life impairment (questions 8 to 10 of the ARSSQ).	For each separate symptom, the duration is defined as the number of days between Day 1 and the first day the parent/legal guardian reports the patient not having this symptom ("Not present") for 2 consecutive days.; Duration may be censored at Visit 2.	Through study completion, up to Day 18
Secondary	Frequency and number of days of concomitant treatments use that may affect common cold symptoms (antibiotics, antipyretics, systemic or local mucolytics, decongestants, antitussives, systemic and topical corticosteroids)	Concomitant treatments use will be reported in the paper diary by parents/legal guardians throughout the study, validated by the investigator at the end of the study visit before being reported in the e-CRF.	Through study completion, up to Day 18
Secondary	Safety: adverse events and incidents throughout the study	Assessment of adverse event related to acute rhinitis and incidents throughout the study in both groups.	Through study completion, up to Day 18